Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
thalidomide moiety
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "thalidomide moiety" in MCE Product Catalog:
Cat. No.: HY-W441376
CAS No.: 2244568-06-5
Target:
Research Areas:
Thalidomide-1-Me,4-OH is a Thalidomide (HY-14658) analogue. Thalidomide-1-Me,4-OH contains an extra methyl group on the glutarimide moiety of thalidomide, which is known to abrogate its ability to bind the E3 ligase CRBN. Thalidomide is a ligand for E3 ligase, which ubiquitinylates proteins, thus committing their fate to proteolytic destruction.
Cat. No.: HY-W800655
CAS No.: 2446382-02-9
Target:
Research Areas:
Thalidomide-O-PEG4-Acid is a PROTAC linker that can react with Amine containing moiety in the presence of Activator EDC or HATU.
Cat. No.: HY-187216
Research Areas:
Thalidomide-4-O-C10-piperidine-NHBoc is an intermediate in the synthesis of G9a-targeting PROTAC, and serves as the E3 ligase ligand-linker conjugate moiety for PROTAC G9a degrader-1 (HY-187214) .
Cat. No.: HY-184672
CAS No.: 2357108-46-2
Research Areas:
Thalidomide-NH-C2-NH-C5-NH2 is an E3 ligase ligand-linker conjugate that can be used for PROTAC synthesis. Thalidomide-NH-C2-NH-C5-NH2 serves as the E3 ligase ligand-linker conjugate moiety of PROTAC IRAK4 degrader-6 (HY-139317) .
Cat. No.: HY-185557
CAS No.: 3063448-59-6
Target:
Research Areas:
LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia .
Cat. No.: HY-W597583
CAS No.: 26581-83-9
Target:
Research Areas:
2-(2,6-Dioxopiperidin-3-yl)phthalimidine NMe is an E3 ligase ligand of SIAIS630121-NC (HY-159016). 2-(2,6-Dioxopiperidin-3-yl)phthalimidine NMe contains an extra methyl group on the glutarimide moiety of thalidomide, which is known to abrogate its ability to bind the E3 ligase CRBN. SIAIS630121-NC is a negative control for NAMPT degrader SIAIS630121 .
Cat. No.: HY-180329
CAS No.: 2417296-83-2
Target:
CG 858-Neg (compound 13) is a negative control for Thalidomide (HY-14658)-derived PROTAC degraders, targeting BRAF and BRAF V600E with Ki values of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAF V600E-driven melanoma (e.g., A375 cells, IC50=492 nM) and colorectal cancer (e.g., HT-29 cells, IC50=459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
